<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683707</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00089755</org_study_id>
    <nct_id>NCT02683707</nct_id>
  </id_info>
  <brief_title>The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial (PACIFY)</brief_title>
  <acronym>PACIFY</acronym>
  <official_title>The Platelet Aggregation After tiCagrelor Inhibition and FentanYl Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      With potent analgesic properties, perceived hemodynamic benefits and limited alternatives,
      opiates are the analgesic mainstay for acute coronary syndrome (ACS) patients reporting
      peri-procedural pain or nitrate-resistant chest pain. However, large observational studies
      suggest that opiate administration during ACS may result in adverse cardiovascular outcomes.
      Complimenting this, a number of recent mechanistic studies have demonstrated delayed and
      attenuated effects of oral dual anti-platelet therapy (DAPT) on platelet inhibition endpoints
      among subjects receiving intravenous morphine. These studies support the hypothesis that
      morphine delays the gastrointestinal absorption of DAPT medications. However, no data exist
      on the impact of intravenous fentanyl, a systemic opioid analgesic routinely administered
      during percutaneous coronary intervention (PCI) procedures, on the platelet inhibition
      effects of DAPT. The investigators hypothesize that, similar to morphine, fentanyl
      administered at the time of PCI will reduce and delay the effect of DAPT on platelet
      function. As such, the primary aim of this study is to test the impact of intravenous
      fentanyl on residual platelet reactivity by randomizing patients undergoing PCI to a strategy
      of peri-procedural benzodiazepine plus non-systemic local analgesia or to the current
      standard of benzodiazepine plus intravenous fentanyl. Given the critical need for rapid and
      robust inhibition of platelet function during PCI, this trial has true potential to change
      clinical practice, particularly if the investigators demonstrate reduced DAPT absorption and
      elevated residual platelet reactivity among patients receiving fentanyl during PCI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2016</start_date>
  <completion_date type="Actual">May 25, 2017</completion_date>
  <primary_completion_date type="Actual">May 25, 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ticagrelor Pharmacokinetics</measure>
    <time_frame>Measured over 24 hours (at 0, 0.5, 1, 2, 4, and 24 hours)</time_frame>
    <description>Area under the curve for Ticagrelor Absorption</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single Time-point Platelet Reactivity Using Verify Now</measure>
    <time_frame>Measured at 2 hours</time_frame>
    <description>Blood test of Platelet Cell Reactivity using Verify Now (P2Y12 Reactivity Units)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Platelet Reactivity Using Light Transmission Aggregometry</measure>
    <time_frame>2 hours after ticagrelor loading</time_frame>
    <description>Blood test of Platelet Cell Reactivity using Light Transmission Aggregometry (reported as percent of baseline aggregation in response to adenosine diphosphate stimulation)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Self-reported Pain</measure>
    <time_frame>2 hours</time_frame>
    <description>Patient self report of pain using a visual analog scale (VAS). Scale ranges from 0 to 10 with 0 being &quot;No pain&quot; and 10 being &quot;Most severe pain&quot;.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PCI without IV opiate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCI with IV opiate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Removal of Fentanyl from peri-procedural analgesia</intervention_name>
    <description>Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)</description>
    <arm_group_label>PCI without IV opiate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fentanyl</intervention_name>
    <description>IV peri-procedural analgesia</description>
    <arm_group_label>PCI with IV opiate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Local Anesthetic</description>
    <arm_group_label>PCI without IV opiate</arm_group_label>
    <arm_group_label>PCI with IV opiate</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midazolam</intervention_name>
    <description>IV sedation</description>
    <arm_group_label>PCI without IV opiate</arm_group_label>
    <arm_group_label>PCI with IV opiate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  undergoing clinically indicated PCI; &gt;18 years of age; able for PO medications and to
             provide informed consent

        Exclusion Criteria:

          -  pregnant; any DAPT(clopidogrel, prasugrel, ticagrelor) within 14 days of enrollment;
             known coagulation disorders; active treatment with oral anticoagulant or low molecular
             weight heparin; impaired renal or hepatic function; platelets &lt; 100 x10 3 /mcl;
             planned use of Glycoprotein 2b3a for PCI; Prior Trans Arterial Valve Replacement
             (TAVR) or planned TAVR post PCI; and contraindications to ticagrelor or opiates.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W McEvoy, MBBCh MHS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Hospital and University School of Medicicine</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2016</study_first_submitted>
  <study_first_submitted_qc>February 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <results_first_submitted>April 5, 2018</results_first_submitted>
  <results_first_submitted_qc>May 7, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2018</results_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Blood Platelets</keyword>
  <keyword>Fentanyl</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Anesthetics, Local</mesh_term>
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>PCI Without Intranvenous (IV) Opiate</title>
          <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for percutaneous coronary intervention [PCI])
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
        </group>
        <group group_id="P2">
          <title>PCI With IV Opiate</title>
          <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="105"/>
                <participants group_id="P2" count="107"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>PCI Without IV Opiate</title>
          <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
        </group>
        <group group_id="B2">
          <title>PCI With IV Opiate</title>
          <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="107"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="9.3"/>
                    <measurement group_id="B2" value="63" spread="10.2"/>
                    <measurement group_id="B3" value="64" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="82"/>
                    <measurement group_id="B3" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="79"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="154"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="107"/>
                    <measurement group_id="B3" value="212"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Platelet count</title>
          <units>K/cu mm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="230" spread="59"/>
                    <measurement group_id="B2" value="223" spread="71"/>
                    <measurement group_id="B3" value="226" spread="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ticagrelor Pharmacokinetics</title>
        <description>Area under the curve for Ticagrelor Absorption</description>
        <time_frame>Measured over 24 hours (at 0, 0.5, 1, 2, 4, and 24 hours)</time_frame>
        <population>Only the subgroup (n=70) of enrolled participants who required PCI and were loaded with ticagrelor had information on the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>PCI Without IV Opiate</title>
            <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
          <group group_id="O2">
            <title>PCI With IV Opiate</title>
            <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Ticagrelor Pharmacokinetics</title>
          <description>Area under the curve for Ticagrelor Absorption</description>
          <population>Only the subgroup (n=70) of enrolled participants who required PCI and were loaded with ticagrelor had information on the primary endpoint</population>
          <units>ng*hr/mL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3301" spread="271"/>
                    <measurement group_id="O2" value="2107" spread="301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Single Time-point Platelet Reactivity Using Verify Now</title>
        <description>Blood test of Platelet Cell Reactivity using Verify Now (P2Y12 Reactivity Units)</description>
        <time_frame>Measured at 2 hours</time_frame>
        <population>Only the subgroup (n=70) of enrolled participants who required PCI and were loaded with ticagrelor had information on the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>PCI Without IV Opiate</title>
            <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
          <group group_id="O2">
            <title>PCI With IV Opiate</title>
            <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Single Time-point Platelet Reactivity Using Verify Now</title>
          <description>Blood test of Platelet Cell Reactivity using Verify Now (P2Y12 Reactivity Units)</description>
          <population>Only the subgroup (n=70) of enrolled participants who required PCI and were loaded with ticagrelor had information on the primary endpoint</population>
          <units>PRUs</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="72"/>
                    <measurement group_id="O2" value="112" spread="95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Platelet Reactivity Using Light Transmission Aggregometry</title>
        <description>Blood test of Platelet Cell Reactivity using Light Transmission Aggregometry (reported as percent of baseline aggregation in response to adenosine diphosphate stimulation)</description>
        <time_frame>2 hours after ticagrelor loading</time_frame>
        <population>Only the subgroup (n=70) of enrolled participants who required PCI and were loaded with ticagrelor had information on the primary endpoint</population>
        <group_list>
          <group group_id="O1">
            <title>PCI Without IV Opiate</title>
            <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
          <group group_id="O2">
            <title>PCI With IV Opiate</title>
            <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Platelet Reactivity Using Light Transmission Aggregometry</title>
          <description>Blood test of Platelet Cell Reactivity using Light Transmission Aggregometry (reported as percent of baseline aggregation in response to adenosine diphosphate stimulation)</description>
          <population>Only the subgroup (n=70) of enrolled participants who required PCI and were loaded with ticagrelor had information on the primary endpoint</population>
          <units>percentage of baseline aggregation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="35"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.5" spread="14.4"/>
                    <measurement group_id="O2" value="39.3" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Self-reported Pain</title>
        <description>Patient self report of pain using a visual analog scale (VAS). Scale ranges from 0 to 10 with 0 being &quot;No pain&quot; and 10 being &quot;Most severe pain&quot;.</description>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>PCI Without IV Opiate</title>
            <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
          <group group_id="O2">
            <title>PCI With IV Opiate</title>
            <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Self-reported Pain</title>
          <description>Patient self report of pain using a visual analog scale (VAS). Scale ranges from 0 to 10 with 0 being &quot;No pain&quot; and 10 being &quot;Most severe pain&quot;.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="107"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="3.1"/>
                    <measurement group_id="O2" value="1.5" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data (specifically pain and anxiety reports from participants) were collected on the day of the procedure during which each participant was under study.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>PCI Without IV Opiate</title>
          <description>IV midazolam and Local Anesthetic, with removal of IV fentanyl from peri-procedural analgesia (which is otherwise routinely given)
Removal of Fentanyl from peri-procedural analgesia: Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
        </group>
        <group group_id="E2">
          <title>PCI With IV Opiate</title>
          <description>IV midazolam and Local Anesthetic and IV fentanyl for peri-procedural analgesia
Fentanyl: IV peri-procedural analgesia
Lidocaine: Local Anesthetic
Midazolam: IV sedation</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain &gt;5/10</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="105"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="107"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small sample, surrogate endpoints</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr J William McEvoy</name_or_title>
      <organization>JohnsHopkinsU</organization>
      <phone>4109555000</phone>
      <email>jmcevoy1@jhmi.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

